MIP and neoplasm: In the presence of effective type 1 IFN signaling pathway, MIP immunotherapy remodulates the otherwise immunosuppressed Ti-DCs towards activated and matured form as they are likely rendered refractory to the suppressive effect of the tumor-derived anti-inflammatory molecules.